Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 2/20 | 0.46 |
| ▸ | FABP7 | O15540 | 2/20 | 0.44 |
| ▸ | FABP5 | Q01469 | 2/20 | 0.44 |
| ▸ | FABP3 | P05413 | 1/20 | 0.41 |
| ▸ | CHRM3 | P20309 | 6/20 | 0.40 |
| ▸ | PDE4A | P27815 | 2/20 | 0.38 |
| ▸ | PDE4B | Q07343 | 2/20 | 0.38 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.38 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.38 |
| ▸ | GRM7 | Q14831 | 1/20 | 0.36 |
| ▸ | BCHE | P06276 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18714042 | 0.87 | FABP7 (0.47) | IDO1FABP7FABP5FABP3CHRM3 | |
| SCHEMBL16746603 | 0.80 | RIPK1 (0.42) | IDO1FABP7FABP5FABP3CHRM3 | |
| SCHEMBL18780147 | 0.79 | FABP7 (0.41) | IDO1FABP7FABP5FABP3CHRM3 | |
| SCHEMBL20445664 | 0.77 | FABP7 (0.45) | IDO1FABP7FABP5FABP3CHRM3 | |
| SCHEMBL18714043 | 0.77 | MTNR1A (0.46) | IDO1FABP7FABP5CHRM3 | |
| SCHEMBL1196934 | 0.76 | FABP7 (0.50) | IDO1FABP7FABP5FABP3CHRM3 | |
| SCHEMBL30685660 | 0.76 | IDO1 (0.54) | IDO1FABP7FABP5FABP3PDE4A | |
| SCHEMBL30493000 | 0.76 | FABP7 (0.50) | IDO1FABP7FABP5FABP3CHRM3 | |
| SCHEMBL24326017 | 0.76 | CHRM3 (0.41) | CHRM3 | |
| SCHEMBL28791460 | 0.75 | FABP7 (0.43) | IDO1FABP7FABP5FABP3BCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8778953-B2 | Inhibitors of P38 map kinase | CHROMA THERAPEUTICS LTD. (GB) | 2014-07-15 | — | — | US | disclosed |
| US-8778953-B2 | Inhibitors of P38 map kinase | CHROMA THERAPEUTICS LTD. (GB) | 2014-07-15 | — | — | US | disclosed |
| US-8778953-B2 | Inhibitors of P38 map kinase | CHROMA THERAPEUTICS LTD. (GB) | 2014-07-15 | — | — | US | disclosed |
| EP-2245012-B1 | INHIBITORS OF P38 MAP KINASE | CHROMA THERAPEUTICS LTD (GB) | 2013-07-03 | — | — | EP | disclosed |
| EP-2245012-B1 | INHIBITORS OF P38 MAP KINASE | CHROMA THERAPEUTICS LTD (GB) | 2013-07-03 | — | — | EP | disclosed |
| US-20110034520-A1 | Inhibitors of P38 Map Kinase | MACROPHAGE PHARMA LIMITED (GB) | 2011-02-10 | — | — | US | disclosed |
| US-20110034520-A1 | Inhibitors of P38 Map Kinase | MACROPHAGE PHARMA LIMITED (GB) | 2011-02-10 | — | — | US | disclosed |
| US-20110034520-A1 | Inhibitors of P38 Map Kinase | MACROPHAGE PHARMA LIMITED (GB) | 2011-02-10 | — | — | US | disclosed |
| EP-2245012-A1 | INHIBITORS OF P38 MAP KINASE | Chroma Therapeutics Limited (GB) | 2010-11-03 | — | — | EP | disclosed |
| WO-2009106844-A1 | INHIBITORS OF P38 MAP KINASE | CHROMA THERAPEUTICS LTD. (GB) | 2009-09-03 | — | — | WO | disclosed |
| WO-2009106844-A1 | INHIBITORS OF P38 MAP KINASE | CHROMA THERAPEUTICS LTD. (GB) | 2009-09-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110034520-A1 | Inhibitors of P38 Map Kinase | MAPK3, MAPK1, MAPKAPK3 | IDO1 976/4885FABP7 4775/4885FABP5 4862/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.